MAP2K7(MKK7)
Sign in to save this workspaceUniProt O14733 · PDB · AlphaFold · Substrate: JNK (K55M) · Clone: full-length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Ibrutinib | 94.8% | 5.2% | 94.74 | 0.723 |
| 2 | Lazertinib | 93.8% | 6.2% | 97.47 | 0.674 |
| 3 | Canertinib | 80.6% | 19.4% | 96.49 | 0.671 |
| 4 | Futibatinib | 60.4% | 39.6% | 98.48 | 0.718 |
| 5 | Pemigatinib | 20.1% | 79.9% | 98.23 | 0.718 |
| 6 | Ponatinib | 15.4% | 84.6% | 78.23 | 0.534 |
| 7 | Alpelisib | 12.8% | 87.2% | 97.22 | 0.720 |
| 8 | Zanubrutinib | 12.4% | 87.6% | 98.24 | 0.788 |
| 9 | Pralsetinib | 8.7% | 91.3% | 93.43 | 0.643 |
| 10 | Fedratinib | 8.5% | 91.5% | 96.21 | 0.576 |
| 11 | Capmatinib | 8.4% | 91.6% | 99.75 | 0.582 |
| 12 | Ripretinib | 8.1% | 91.9% | 92.95 | 0.674 |
| 13 | Mitapivat | 7.3% | 92.7% | 100.00 | 0.625 |
| 14 | Neratinib | 7.1% | 92.9% | 93.18 | 0.597 |
| 15 | Pexidartinib | 5.0% | 95.0% | 99.49 | 0.631 |
| 16 | Defactinib | 4.5% | 95.5% | 92.68 | 0.450 |
| 17 | Pacritinib | 4.3% | 95.7% | 88.64 | 0.452 |
| 18 | Brigatinib | 4.3% | 95.7% | 82.96 | 0.513 |
| 19 | Remibrutinib | 4.2% | 95.8% | 99.50 | 0.721 |
| 20 | Gilteritinib | 3.7% | 96.3% | 88.97 | 0.506 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 3.74
- Epithelial log2(TPM+1): 3.92
- Fold change: -0.18
- Status: No significant change
Selectivity landscape vs inhibition on MAP2K7
Each point is one of the 92 approved drugs; color = inhibition % on MAP2K7.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…